Mode
Text Size
Log in / Sign up

Alzheimer's Disease

Part of Dementia

Subtypes of Alzheimer's Disease

Autosomal Dominant Alzheimer's Disease 3 Late-onset Alzheimer's disease 1 Mild dementia due to Alzheimer's disease 1

109 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Alzheimer's Disease

440 trials tracked for Alzheimer's Disease: 98 in phase 3 or 4 and 27 with published results. The most-cited published study has 567 citations.

440Trials tracked
98Phase 3 & 4
0Recruiting
27With published results
Phase distribution
Phase 4 34 Phase 3 64 Phase 2 149 Phase 1 58 Other / NA 135
  1. Phase 3 A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease Completed · 567 cited
  2. Phase 3 18F-AV-1451 Autopsy Study Completed · 442 cited
  3. Phase 3 The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF) Completed · 363 cited
  4. Phase 3 Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease Completed · 350 cited
  5. Phase 3 Depression in Alzheimer's Disease-2 Completed · 244 cited
  6. Phase 3 A Study of Gantenerumab in Participants With Mild Alzheimer Disease Completed · 212 cited
Show 44 more trials
  1. Phase 3 Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061) Completed · 185 cited
  2. Phase 3 Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil Completed · 160 cited
  3. Phase 3 Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor Completed · 160 cited
  4. Phase 3 Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil Completed · 160 cited
  5. Phase 3 Apathy in Dementia Methylphenidate Trial 2 Completed · 109 cited
  6. Phase 3 The Healthy Patterns Sleep Study Completed · 70 cited
  7. Phase 3 Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease Completed · 53 cited
  8. Phase 3 Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects Completed · 53 cited
  9. Phase 4 Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care Completed · 36 cited
  10. Phase 3 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Completed · 28 cited
  11. Phase 3 A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) Completed · 18 cited
  12. Phase 4 Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease Completed · 15 cited
  13. Phase 4 Detecting an Early Response to Donepezil With Measures of Visual Attention Completed · 13 cited
  14. Phase 3 A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease Completed · 13 cited
  15. Phase 3 A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Completed · 13 cited
  16. Phase 3 Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Completed · 11 cited
  17. Phase 4 Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly Completed · 8 cited
  18. Phase 3 ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease Completed · 5 cited
  19. Phase 3 Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease Completed · 2 cited
  20. Phase 3 A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation Completed · 1 cited
  21. Phase 4 Monitoring Anti-Dementia Drugs by Serum Levels Completed
  22. Phase 4 Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease Completed
  23. Phase 4 Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training Completed
  24. Phase 4 Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline Completed
  25. Phase 4 Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia Completed
  26. Phase 4 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients Completed
  27. Phase 4 Effects of Simvastatin on Biomarkers Completed
  28. Phase 4 Trial of Carvedilol in Alzheimer's Disease Completed
  29. Phase 4 Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's Completed
  30. Phase 4 Neural Correlates In Mild Alzheimer's Disease Completed
  31. Phase 4 A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type. Completed
  32. Phase 4 Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease Completed
  33. Phase 4 Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease Completed
  34. Phase 4 The Feasibility of Florbetapir Quantitation in Europe Completed
  35. Phase 4 Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease Completed
  36. Phase 4 Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease Completed
  37. Phase 4 Cilostazol Augmentation Study in Dementia Completed
  38. Phase 4 Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 Completed
  39. Phase 4 Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT) Completed
  40. Phase 4 A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA) Completed
  41. Phase 4 Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study Completed
  42. Phase 4 Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease Completed
  43. Phase 4 The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease Completed
  44. Phase 4 A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease Completed

Showing the 50 most-cited and recently-updated of 440 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Questions about Alzheimer's Disease

Is there a genetic link between kidney function and Alzheimer Disease for my family?

Current research finds no overall genetic link between kidney function and Alzheimer disease, though some shared biological pathways may exist.

Full answer →
Does having brain reserve protect me from Alzheimer Disease symptoms if I am inactive?

Research shows that having more brain reserve, such as from higher education, can help maintain cognitive function even when Alzheimer's disease pathology is present, even in people who are physically inactive.

Full answer →
Are there new genetic markers for Alzheimer disease found in veteran populations?

Yes, a meta-analysis of the VA Million Veterans Program identified 17 new genetic loci in European, 4 in African, and 3 in Hispanic veteran populations for Alzheimer's disease.

Full answer →
Do genetic tests find new risk factors for Alzheimer's in veteran populations?

Yes, genetic tests can find new risk factors for Alzheimer's in veteran populations, as shown by a meta-analysis including the VA Million Veterans Program that identified 17 new genetic loci in European ancestry veterans.

Full answer →
What is the new FDA-approved medication for agitation in Alzheimer's disease?

The FDA has approved Auvelity (dextromethorphan/bupropion) for treating agitation in Alzheimer's disease, making it the first medication specifically approved for this indication.

Full answer →
Can exercise programs really improve sleep quality for people with Alzheimer's disease?

Yes, exercise programs can improve subjective sleep quality in people with Alzheimer's disease, based on a meta-analysis of 12 randomized trials showing a significant reduction in PSQI scores.

Full answer →
See all 6 questions about Alzheimer's Disease →

All Alzheimer's Disease Articles